By the conclusion of this video, you'll be able to describe the different stages of
a drug hunting program. You will also be able to list representative pre-clinical
safety studies that are performed
at each stage. Finally, you will
be able to outline the oversight role of
regulatory agencies. Drug discovery and
development are often described as a pipeline. On the screen is a pipe it starts with a
chemical species on the left and finishes with a
drug product on the right. The process starts with the discovery phase during which large numbers of
molecules are screened. Leads are selected
and optimized and a final lead compound is chosen following
a successful IND, investigational new drug
application in the US or CTA clinical trial application
in many other countries, the clinical candidate
advances through the various phases
of clinical trials. During the development phase, data from the discovery
and development phases are compiled in the NDA
new drug application, or MAA marketing
authorization application. The US and other
countries respectively. Approved drugs are then launch to meet unmet medical needs. Let's see where
pre-clinical safety testing occurs along this pathway. Here is the same graphic with call-outs for specific
safety tests. All the listed items fall under the umbrella of
pre-clinical safety. We want to mention
each of these items, but let's hit some highlights. Early discovery testing
focuses on in vitro testing. Secondary pharmacology
test screen molecules against a group of targets and pathways that are frequently associated
with adverse effects. In vitro genotoxicity would
include the Ames test, which is an assay
for mutagenicity and therefore a potential
indicator for cancer risks. In late discovery, safety pharmacology refers to in vivo test for
short-term cardiac, neurological, and
respiratory risks. These are key tests for a successful IND
application or CTA. If a molecule advances
into the clinic, longer pre-clinical studies will be performed in parallel. Some of these are
standardized tests, while others may be designed
to answer questions specific to the action of
the clinical candidate. Examples include
monitoring compounds, potential reproductive, embryo, fetal, and
developmental effects. These studies is assess
risk to women of child-bearing potential for
adverse reproductive effects. As a molecule advances
into phase III and if the molecule is
intended for chronic use, that is six months or longer. Long-term, two-year duration, carcinogenicity tests
will be performed. Pre and postnatal
toxicology studies are also performed concurrently with later clinical trials. Two of the most commonly
mentioned regulatory agencies, or the US Food and
Drug Administration, FDA and European
Medicines Agency, EMA. The FDA, EMA and other
drug regulatory agencies oversee the safety standards of new and existing drugs
within their jurisdictions. The standards of
the FDA and EMA are requirements that a drug
sponsor must meet as the FDA and EMA
have the authority to deny or revoke drug approval. Distinct from
regulatory agencies is the International Council
for Harmonization of Technical Requirements
for Human Use, the ICH. The ICH strives to develop common guidelines
that are acceptable to many regulatory agencies. Such guidelines
facilitate the creation of new drugs while minimizing the need for different testing for each regulatory agency. Many tests for safety
and efficacy must be performed according
to good practices, which are noted as GxP. The x is a wildcard that denotes a specific
type of practice, for example GLP stands for
good laboratory practice. GxP, are quality guidelines that ensure an activity is
properly documented. Pre-clinical safety studies that directly support
clinical studies are generally required to
follow GLP guidelines. Other GxPs are relevant
to drug programs. Drugs are synthesized and
formulated under GMP, good manufacturing
practice guidelines. Clinical trials are
performed under good clinical practice
or GCP guidelines. FDA, EMA, and ICH documents
specify required GxP is needed for each
stage of a drug program. Safety risks during pre-clinical
studies are minimized through a robust pre-clinical
safety testing program. For this reason, pre-clinical
safety results are closely monitored by drug regulatory
agencies worldwide.